JASN:AKI的亚型由转录程序确定?

2017-06-26 许奕晗 MedSci原创

大家都知道血肌酐浓度升高和尿量减少这两个指标被看做是变相的肾小管及其上皮细胞的损伤(AKI)。然而并没有标准强调肾排泄功能急性下降的病因或致病的异质性。事实上,细胞外液体积减少(vAKI)或内在肾脏损伤(iAKI)导致的排泄功能下降是否有相同发病机制、是否应放在相同的诊断组仍然是一个悬而未决的问题。

大家都知道血肌酐浓度升高和尿量减少这两个指标被看做是变相的肾小管及其上皮细胞的损伤(AKI)。然而并没有标准强调肾排泄功能急性下降的病因或致病的异质性。事实上,细胞外液体积减少(vAKI)或内在肾脏损伤(iAKI)导致的排泄功能下降是否有相同发病机制、是否应放在相同的诊断组仍然是一个悬而未决的问题。

为了检验这种可能性,我们建造了血肌酐浓度增加类似的iAKI或vAKI的小鼠模型。在RNA测序后,采用激光显微切割技术分离肾脏的特定区域,我们发现有成千上万的对于iAKI或vAKI发生特异反应的基因,但是几乎没有对两者都有反应的基因。而且事实上,激活的基因的组成不同、信号转导通路功能不相关、在肾内表达部位也不相同。

此外,我们发现人体尿液中独特的基因表达模式可能是iAKI或vAKI的潜在生物标志物,但不会是同时是两者的。因此,iAKI或vAKI在生物学上并不相关,也提示了应该用分子分析明确我国目前肾排泄功能急性改变的定义。

原始出处:
Katherine Xu.et al.Unique Transcriptional Programs Identify Subtypes of AKI.J AM SOC NEPHROL.2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747252, encodeId=fb531e4725211, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Jun 09 07:09:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941322, encodeId=ee9a194132261, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Tue May 22 08:09:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341099, encodeId=30fe134109960, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Wed Jun 28 08:09:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215670, encodeId=64082156e056, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbkwiamQRUZ02EtNQ6eQflk4CHafHibKTV9ju5ia6AkEvQuZagYnTGsFTuibpHDwZUicuFmVBsIZ0qbJg/0, createdBy=bc812071404, createdName=xuyihan, createdTime=Mon Jun 26 18:53:01 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
    2018-06-09 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747252, encodeId=fb531e4725211, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Jun 09 07:09:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941322, encodeId=ee9a194132261, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Tue May 22 08:09:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341099, encodeId=30fe134109960, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Wed Jun 28 08:09:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215670, encodeId=64082156e056, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbkwiamQRUZ02EtNQ6eQflk4CHafHibKTV9ju5ia6AkEvQuZagYnTGsFTuibpHDwZUicuFmVBsIZ0qbJg/0, createdBy=bc812071404, createdName=xuyihan, createdTime=Mon Jun 26 18:53:01 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
    2018-05-22 chenhongpeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747252, encodeId=fb531e4725211, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Jun 09 07:09:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941322, encodeId=ee9a194132261, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Tue May 22 08:09:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341099, encodeId=30fe134109960, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Wed Jun 28 08:09:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215670, encodeId=64082156e056, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbkwiamQRUZ02EtNQ6eQflk4CHafHibKTV9ju5ia6AkEvQuZagYnTGsFTuibpHDwZUicuFmVBsIZ0qbJg/0, createdBy=bc812071404, createdName=xuyihan, createdTime=Mon Jun 26 18:53:01 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747252, encodeId=fb531e4725211, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Jun 09 07:09:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941322, encodeId=ee9a194132261, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Tue May 22 08:09:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341099, encodeId=30fe134109960, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Wed Jun 28 08:09:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215670, encodeId=64082156e056, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbkwiamQRUZ02EtNQ6eQflk4CHafHibKTV9ju5ia6AkEvQuZagYnTGsFTuibpHDwZUicuFmVBsIZ0qbJg/0, createdBy=bc812071404, createdName=xuyihan, createdTime=Mon Jun 26 18:53:01 CST 2017, time=2017-06-26, status=1, ipAttribution=)]
    2017-06-26 xuyihan

    不错不错

    0

相关资讯

Crit Care:早期和晚期肾替代治疗对心脏手术后急性肾损伤患者死亡率的影响!

由此可见,早期开始RRT治疗可以降低28天的死亡率,尤其是当它在心脏手术后发生AKI的患者发病24小时内。

JAHA:血管成形术后急性肾损伤:造影剂肾病是罪魁祸首吗?

由此可见,接受PCI的ST段抬高型心肌梗死的患者发生AKI主要与年龄较大、基础估计肾小球滤过率、心力衰竭、血流动力学不稳定相关。在ST段抬高心肌梗死的患者中无论有无造影剂暴露,其发生AKI的风险相似。

Chest:尿量的强化监测与增加急性肾损伤的检测和改善预后有关

在大型ICU人群中,强化UO监测与改善的AKI检测相关,并且可以降低发生AKI患者以及较少的液体超负荷的患者的30天死亡率。该研究结果应该有助于指导临床决策和ICU政策,关于监测UO频率,尤其是AKI和/或液体超负荷的高危患者。

Kidney Int:重组α-Klotho有望成为预防和治疗急性向慢性肾脏疾病发展及尿毒症性心肌病的新选择

α-Klotho高表达于肾脏,它的胞外区域可以被切断并释放到循环中。慢性肾脏疾病(CKD)的一个特征即为α-Klotho缺失,它对众多脏器表现出多重的负面系统效应,包括心血管系统。

Intens Care Med:ICU急性肾损伤的预防与肾功能的保护!

由此可见,最近的随机对照试验的结果允许制定新的建议和/或增加以前的建议的强度。另一方面,在许多领域,现有可用的证据仍然不足,主要是由于质量受限的临床试验和报告的不良肾脏结局。

KIDNEY INT:流行病学研究表明AKI的发病率并没有增加!

因此,尽管目前的文献表明AKI的流行,研究人员发现将年龄、性别进行调整后,在过去的十年间AKI的发病率在一般人群中保持相对稳定。